3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Endometrial Neoplasms
15
Ovarian Neoplasms
11
Uterine Cervical Neoplasms
5
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Neoplasms
2
Colorectal Neoplasms
2
Carcinoma
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Turcot syndrome
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Ovarian Carcinosarcoma
1
MMRd/MSI-H Stage II-III Endometrial Cancer
1
Lung Neoplasms
1
Gestational Trophoblastic Disease
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma, Clear Cell
1
Interventions
Paclitaxel
2
Nivolumab
2
Gemcitabine
2
Bevacizumab
2
rucaparib
1
pembrolizumab
1
liposomal doxorubicin
1
dostarlimab
1
Taxes
1
Sunitinib
1
Ipilimumab
1
Immunoglobulin G
1
Doxorubicin
1
Docetaxel
1
Disulfides
1
Celecoxib
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma, Clear Cell
×
dostarlimab
×
Gynecologic
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled